Lynelle Hoch, president of Bristol Myers Squibb's cell therapy organization
October 23, 2026 02:36 PM EDT
Q&A: Bristol Myers’ Lynelle Hoch on autoimmune CAR-T safety challenges, new patient death
Bristol Myers Squibb is facing one problem after another with its autoimmune CAR-T therapy program. The company says it has figured out …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source
ENDPOINTS CAREERS